Vaccines

The biopharma company shatters records with 51% growth in its key drug, ASCENIV, and outlines a strategic overhaul aimed at long-term market dominance.

With a massive late-stage pipeline and deep pockets, the biotech aims to defeat elusive cancer targets, but soaring costs raise the stakes for pivotal trials.

Eton Pharmaceuticals wins landmark FDA approval for DESMODA, a breakthrough liquid drug set to transform care for a rare condition by enabling precise, safe dosing.

A new oral drug shows remarkable success in healing stubborn herpes lesions in people with HIV, offering a much-needed breakthrough for a vulnerable population.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

New subgroup data from ITM's COMPETE trial could refine treatment for a tough-to-treat cancer and bolster the company's position in the radiopharma market.

As Evolus presents at a key healthcare conference, investors watch to see if its new filler line and digital strategy can deliver on bold promises.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

New research reveals how stomach cancer cells hijack healthy tissue to build supportive 'nests' in distant organs, opening a new front in the war on metastasis.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.

A newly identified blood biomarker for the drug masitinib could revolutionize how doctors treat ALS, progressive MS, and Alzheimer's disease.

Dupixent's landmark FDA approval offers a new, surgery-sparing option for a debilitating sinus disease, but questions of access and cost remain.

Despite missing its primary goal, Cadrenal Therapeutics' drug CAD-1005 drastically cut deadly blood clots, setting up a crucial FDA meeting for a new path forward.

A new report on 1,800+ patients reveals a model for obesity care that preserves muscle, sustains weight loss, and may solve the GLP-1 cost crisis.

The maker of Wegovy and Ozempic announces a massive price cut. We explore what this means for patients, competitors, and the future of drug pricing.

Swiss biotech AC Immune begins a human trial for an oral drug aiming to halt the chronic inflammation driving diseases like Alzheimer's and Parkinson's.

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.

A Korean firm says it can cure 34 diseases using cells from cloned embryos, walking a fine line between a medical breakthrough and a bioethical taboo.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.